Levodopa Equivalent Dose of Safinamide: A Multicenter, Longitudinal, Case-Control Study

Area of Science:

• Neurology
• Pharmacology
• Clinical Research

Background:

• Levodopa equivalent dose (LED) is crucial for comparing dopaminergic medications in Parkinson's disease (PD).
• Current LED estimations for MAO-B inhibitors (iMAO-B) like safinamide and rasagiline rely on empirical methods.
• Standardized LED conversion factors are needed for these iMAO-B treatments.

Purpose of the Study:

• To estimate the Levodopa equivalent dose (LED) for safinamide at 50mg and 100mg doses.
• To provide a more rigorous basis for comparing safinamide with other iMAO-B treatments.

Main Methods:

• A multicenter, longitudinal, case-control study involving 500 PD patients with motor complications.
• Retrospective review of clinical charts for patients treated with safinamide (50mg or 100mg), rasagiline (1mg), or no iMAO-B.
• Analysis of clinical outcomes and medication dosages over an 8-10 month follow-up period.

Main Results:

• After adjusting for baseline and clinical factors, safinamide 100mg was found to be equivalent to 125mg LED.
• Safinamide 50mg and rasagiline 1mg were found to be equivalent to 100mg LED.
• Patients on safinamide showed improvements in motor function scores (UPDRS-III) and reduced OFF-time (UPDRS-IV) compared to controls.

Conclusions:

• A rigorous method was employed to calculate LED for safinamide 50mg and 100mg.
• The findings provide valuable LED conversion factors for safinamide in PD management.
• Prospective pragmatic trials are recommended to validate these LED estimations.